FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890693336> ?p ?o ?g. }

• W2890693336 endingPage "99" @default.
• W2890693336 startingPage "94" @default.
• W2890693336 abstract "Investigators are using checkpoint inhibitors (CPIs) to treat aggressive hematologic malignancies in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT) and in some patients with relapsed disease after allo-HSCT. CTLA-4 inhibitors and PD-1 inhibitors are 2 main types of CPIs, which work through activation of the immune system. On one hand, CPIs can achieve graft-versus-tumor effect, and on the other hand, there is a risk of graft-versus-host disease (GVHD). After a comprehensive literature review, we included data (n = 283) from 24 studies (11 original manuscripts and 13 case reports or case series) and evaluated the results to assess the safety and efficacy of CPI use in conjunction with allo-HSCT. Among the 283 patients, 107 received CPI before allo-HSCT, and 176 received CPI after allo-HSCT. The most common indication for CPI use was for Hodgkin lymphoma. The CPIs used in various studies included ipilimumab, nivolumab, and pembrolizumab. Among the patients exposed to CPI before allo-HSCT, 56% developed acute GVHD and 29% developed chronic GVHD. Investigators reported 20 deaths, 60% of which were GVHD-related. The overall mortality risk with GVHD is 11%. In this group, investigators noted an objective response rate (ORR) in 68% of patients, with complete remission (CR) in 47%, partial remission (PR) in 21%, and stable disease in 11%. Among the patients who received a CPI after allo-HSCT for disease relapse, 14% developed acute GVHD and 9% developed chronic GVHD. Investigators reported 40 deaths, 28% of which were GVHD-related. The mortality risk with GVHD is approximately 7%. Investigators reported ORR in 54% of patients, with CR in 33%, PR in 21%, and disease stabilization in 5%. After careful evaluation of collective data, we found that CPI use both before and after allo-HSCT can be highly effective, but exposure can lead to a significantly increased risk of GVHD-related morbidity and mortality in this patient population. Despite limited availability of data, there is need for extreme caution while making decisions regarding the use of CPIs. Detailed discussions and prospective well-designed clinical trials are needed to explore this issue further." @default.
• W2890693336 created "2018-09-27" @default.
• W2890693336 creator A5003646491 @default.
• W2890693336 creator A5005991606 @default.
• W2890693336 creator A5009003215 @default.
• W2890693336 creator A5016687353 @default.
• W2890693336 creator A5018307896 @default.
• W2890693336 creator A5018470139 @default.
• W2890693336 creator A5019180708 @default.
• W2890693336 creator A5020767131 @default.
• W2890693336 creator A5031094511 @default.
• W2890693336 creator A5041198052 @default.
• W2890693336 creator A5041626144 @default.
• W2890693336 creator A5049387929 @default.
• W2890693336 creator A5056366470 @default.
• W2890693336 creator A5061055639 @default.
• W2890693336 creator A5069644314 @default.
• W2890693336 creator A5088754139 @default.
• W2890693336 date "2019-01-01" @default.
• W2890693336 modified "2023-10-17" @default.
• W2890693336 title "Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic Transplantation" @default.
• W2890693336 cites W1973248441 @default.
• W2890693336 cites W2065386296 @default.
• W2890693336 cites W2067948267 @default.
• W2890693336 cites W2113946521 @default.
• W2890693336 cites W2130562921 @default.
• W2890693336 cites W2168557022 @default.
• W2890693336 cites W2196097627 @default.
• W2890693336 cites W2258040653 @default.
• W2890693336 cites W2261336475 @default.
• W2890693336 cites W2343568367 @default.
• W2890693336 cites W2465734185 @default.
• W2890693336 cites W2490883346 @default.
• W2890693336 cites W2521963948 @default.
• W2890693336 cites W2559063149 @default.
• W2890693336 cites W2559870972 @default.
• W2890693336 cites W2567998110 @default.
• W2890693336 cites W2577999417 @default.
• W2890693336 cites W2583124762 @default.
• W2890693336 cites W2585608532 @default.
• W2890693336 cites W2586276931 @default.
• W2890693336 cites W2594496276 @default.
• W2890693336 cites W2603016973 @default.
• W2890693336 cites W2606390807 @default.
• W2890693336 cites W2610082331 @default.
• W2890693336 cites W2611116831 @default.
• W2890693336 cites W2611189127 @default.
• W2890693336 cites W2624338603 @default.
• W2890693336 cites W2731673561 @default.
• W2890693336 cites W2773645448 @default.
• W2890693336 cites W2802434483 @default.
• W2890693336 doi "https://doi.org/10.1016/j.bbmt.2018.08.028" @default.
• W2890693336 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6310648" @default.
• W2890693336 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30195074" @default.
• W2890693336 hasPublicationYear "2019" @default.
• W2890693336 type Work @default.
• W2890693336 sameAs 2890693336 @default.
• W2890693336 citedByCount "126" @default.
• W2890693336 countsByYear W28906933362019 @default.
• W2890693336 countsByYear W28906933362020 @default.
• W2890693336 countsByYear W28906933362021 @default.
• W2890693336 countsByYear W28906933362022 @default.
• W2890693336 countsByYear W28906933362023 @default.
• W2890693336 crossrefType "journal-article" @default.
• W2890693336 hasAuthorship W2890693336A5003646491 @default.
• W2890693336 hasAuthorship W2890693336A5005991606 @default.
• W2890693336 hasAuthorship W2890693336A5009003215 @default.
• W2890693336 hasAuthorship W2890693336A5016687353 @default.
• W2890693336 hasAuthorship W2890693336A5018307896 @default.
• W2890693336 hasAuthorship W2890693336A5018470139 @default.
• W2890693336 hasAuthorship W2890693336A5019180708 @default.
• W2890693336 hasAuthorship W2890693336A5020767131 @default.
• W2890693336 hasAuthorship W2890693336A5031094511 @default.
• W2890693336 hasAuthorship W2890693336A5041198052 @default.
• W2890693336 hasAuthorship W2890693336A5041626144 @default.
• W2890693336 hasAuthorship W2890693336A5049387929 @default.
• W2890693336 hasAuthorship W2890693336A5056366470 @default.
• W2890693336 hasAuthorship W2890693336A5061055639 @default.
• W2890693336 hasAuthorship W2890693336A5069644314 @default.
• W2890693336 hasAuthorship W2890693336A5088754139 @default.
• W2890693336 hasBestOaLocation W28906933361 @default.
• W2890693336 hasConcept C121608353 @default.
• W2890693336 hasConcept C126322002 @default.
• W2890693336 hasConcept C143998085 @default.
• W2890693336 hasConcept C2777408962 @default.
• W2890693336 hasConcept C2777701055 @default.
• W2890693336 hasConcept C2779134260 @default.
• W2890693336 hasConcept C2779338263 @default.
• W2890693336 hasConcept C2779972918 @default.
• W2890693336 hasConcept C2780030458 @default.
• W2890693336 hasConcept C2780057760 @default.
• W2890693336 hasConcept C2781433595 @default.
• W2890693336 hasConcept C2911091166 @default.
• W2890693336 hasConcept C71924100 @default.
• W2890693336 hasConceptScore W2890693336C121608353 @default.
• W2890693336 hasConceptScore W2890693336C126322002 @default.
• W2890693336 hasConceptScore W2890693336C143998085 @default.
• W2890693336 hasConceptScore W2890693336C2777408962 @default.

• next